MAHONEY DAVID L 4
4 · CORCEPT THERAPEUTICS INC · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
Corcept (CORT) Director David Mahoney Sells 20,000 Shares
What Happened
David L. Mahoney, a director of Corcept Therapeutics, reported an open-market sale of 20,000 common shares on June 17, 2026. The weighted average sale price was $84.53, for total proceeds of $1,690,506. The filing indicates the sale was a disposition (code S).
Key Details
- Transaction date: 2026-06-17 (reported on Form 4 filed 2026-06-18) — filing appears timely.
- Transaction type: Open-market sale (S).
- Shares sold: 20,000; weighted average price: $84.53; total proceeds: $1,690,506.
- Price range: individual sale prices ranged from $84.44 to $85.11 (see footnote F1). Exact allocation by price not provided; issuer can supply details on request.
- Shares owned after transaction: Not specified in this filing.
- Remarks: Power of attorney under which the form was signed is on file with the SEC.
Context
This was a straightforward open-market sale by a company director. Sales can reflect many non-investment reasons (diversification, personal needs, pre-set plans); they are not by themselves a clear bearish signal. There is no indication in the filing of an option exercise, 10b5‑1 plan, gift, or late filing.
Insider Transaction Report
Form 4
MAHONEY DAVID L
Director
Transactions
- Sale
Common Stock
[F1]2026-06-17$84.53/sh−20,000$1,690,506→ 26,147 total(indirect: By Foundation)
Holdings
- 1,237,145(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.44 to $85.11. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for David L Mahoney|2026-06-18